Holy Cross Health is now offering a new miniaturized, wireless monitoring sensor to manage heart failure. The Abbott CardioMEMS™ HF System is the first and only FDA-approved heart failure monitoring device that has been clinically proven to significantly reduce hospital admissions when used by physicians to manage heart failure.
Heart failure is the leading cause of hospitalization for Americans over age 65. The device allows patients to remotely share daily sensor readings from their homes to their health care providers, allowing for personalized care to reduce the likelihood of hospitalization. Innovative telehealth, like the CardioMEMS HF System, reduces the need for in-person appointments. Data from a recent clinical trial found that the remote monitoring technology reduces heart failure hospital admissions by up to 58 percent.
Heart failure occurs when the heart is unable to pump enough blood to meet the body’s demands. The CardioMEMS HF System features a sensor that is implanted in the pulmonary artery (PA) during a minimally invasive procedure. Increased PA pressures appear before weight and blood pressure changes, which are often used as indirect measures of worsening heart failure.
According to the American Heart Association, nearly six million Americans have heart failure and 900,000 new patients are diagnosed each year. The Centers for Disease Control and Prevention cite that half of heart failure patients die within five years of diagnosis. The estimated cost of heart failure in the U.S. is expected to double by 2030.
“Holy Cross Health is committed to improving patient care and investing in innovative medical technology such as the CardioMEMS HF System,” said Mark Doyle, President and CEO of Holy Cross Health. “We strive to always find solutions for successful patient outcomes in the diagnosis or treatment of heart failure.”
Bruno Zupp from Coral Springs initially sought treatment at Holy Cross because he was having trouble breathing and walking which resulted in a 20+ pound weight gain caused by his heart retaining fluid. “If you are experiencing weight gain and your heart isn’t functioning properly, get this procedure done as soon as possible,” said Zupp. “It was an easy, out-patient procedure that was not painful and the doctors at Holy Cross are fantastic.”
The CardioMEMS HF System, from global health care leader Abbott, is approved by the U.S. Food and Drug Administration (FDA) for commercial use in the U.S. The GUIDE-HF clinical trial followed the CHAMPION trial, which studied the effectiveness of the CardioMEMS HF System in New York Heart Association (NYHA) Functional Classification System class III heart failure patients who had been hospitalized for heart failure in the previous 12 months.
About Holy Cross Health:
A member of Trinity Health, Fort Lauderdale-based Holy Cross Hospital, dba Holy Cross Health, is a full-service, non-profit, Catholic, teaching hospital operating in the spirit of the Sisters of Mercy. Holy Cross has been named one of the top 10 hospitals in the Miami metro area and among the top 30 in the state in U.S. News and World Report’s 2020-2021 Best Hospital rankings. Through strategic collaborations and a commitment to being a person-centered, transforming, healing presence, the 557-bed hospital offers progressive inpatient, outpatient and community outreach services and clinical research trials to serve as our community’s trusted health partner for life. Holy Cross Health also encompasses Holy Cross HealthPlex outpatient facility, urgent care centers and more than 50 Holy Cross Medical Group physician practices. To learn more about Holy Cross Health, visit holy-cross.com. Connect @holycrossfl.
About Abbott:
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 109,000 colleagues serve people in more than 160 countries.
